...
机译:venetoclax-Obinutuzumab在预先治疗和复发的/难治性慢性淋巴细胞白血病中的第1B期研究
Sarah Cannon Res Inst Nashville TN USA;
Queen Mary Univ London Barts Canc Inst London England;
Univ Leicester Ernest &
Helen Scott Haematol Res Inst Leicester Leics England;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Colorado Blood Canc Inst Sarah Cannon Res Inst Denver CO USA;
Weill Cornell Med CLL Res Ctr New York NY USA;
St James Univ Hosp Leeds W Yorkshire England;
Ohio State Univ Div Hematol Columbus OH 43210 USA;
Houston Methodist Hosp Houston TX USA;
Univ Toulouse III Paul Sabatier Canc Res Ctr Toulouse Toulouse France;
Univ Toulouse III Paul Sabatier Canc Res Ctr Toulouse Toulouse France;
Univ Leicester Ernest &
Helen Scott Haematol Res Inst Leicester Leics England;
AbbVie N Chicago IL USA;
Roche Innovat Ctr Zurich Roche Pharma Res &
Early Dev Schlieren Switzerland;
F Hoffmann Roche Ltd Mississauga ON Canada;
Genentech Inc San Francisco CA 94080 USA;
Ohio State Univ Dept Pathol Columbus OH 43210 USA;
Roche Prod Ltd Welwyn Garden City Herts England;
Roche Prod Ltd Welwyn Garden City Herts England;
Genentech Inc San Francisco CA 94080 USA;
Univ Calif San Diego Sch Med San Diego CA 92103 USA;
机译:venetoclax-Obinutuzumab在预先治疗和复发的/难治性慢性淋巴细胞白血病中的第1B期研究
机译:venetoclax与Rituximab在复发或难治性慢性淋巴细胞白血病患者组合的曝光 - 反应分析:合并结果来自第1B期研究和第3期穆拉诺研究
机译:opeutuzumab,伊布勒替尼和威尼替肽在复发和难治性慢性淋巴细胞白血病中的第1B期研究
机译:在未经治疗的慢性淋巴细胞性白血病患者的CT扫描中自动检测腋窝淋巴结肿大
机译:绝经后妇女慢性淋巴细胞白血病和小淋巴细胞淋巴瘤发生率的危险因素:妇女健康倡议(WHI)研究
机译:Venetoclax-obinutuzumab在先前未治疗和复发/难治的慢性淋巴细胞性白血病中的1b期研究
机译:在复发和难治性慢性淋巴细胞白血病中,Obinutuzumab,Ibrutinib和venetoclax的第1B期研究